source
- Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapiesEli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
- Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseasesBiogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…